Eli Lilly nears $2B-plus deal for Kelonia to expand cancer pipeline: WSJ (LLY:NYSE)
Summary
Eli Lilly is in talks to buy Kelonia Therapeutics for $2B+, boosting its oncology pipeline with next-gen CAR-T for multiple myeloma.
Description
Eli Lilly is in talks to buy Kelonia Therapeutics for $2B+, boosting its oncology pipeline with next-gen CAR-T for multiple myeloma.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source